<?xml version="1.0" encoding="UTF-8"?><urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9"><url><loc>https://mindmedicinelaw.com/briefing/ketamine-and-esketamine-for-treatment-resistant-depression-evidence-gaps-and-cli-20261122-61123</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-22T22:04:30.098091+00:00</news:publication_date><news:title>Ketamine and Esketamine for Treatment-Resistant Depression: Evidence, Gaps, and Clinical Implications (2026 Review)</news:title><news:keywords>ketamine, esketamine, treatment-resistant depression, rapid-acting antidepressants, clinical trials, safety profile, comparative efficacy, maintenance therapy, regional data gaps</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/non-hallucinogenic-ketamine-for-trauma-israeli-clinical-trials-and-global-implic-20261122-61035</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-22T15:04:06.315414+00:00</news:publication_date><news:title>Non-Hallucinogenic Ketamine for Trauma: Israeli Clinical Trials and Global Implications</news:title><news:keywords>ketamine, non-hallucinogenic, israel, trauma treatment, clinical trials, psychedelic research, regulatory policy, ptsd, neuropharmacology</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/chronic-heat-exposure-lowers-serotonin-2a-receptor-in-mice-20261120-61111</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-22T22:05:13.081272+00:00</news:publication_date><news:title>Chronic Heat Exposure Lowers Serotonin 2A Receptor in Mice</news:title><news:keywords>serotonin 2a receptor, htr2a, chronic heat exposure, prelimbic cortex, parvalbumin neurons, psychedelic research, anxiety phenotypes, environmental stress, clinical trial design</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/spin-meta-analysis-validates-social-anxiety-screening-in-trials-20261120-61096</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-22T22:04:58.521551+00:00</news:publication_date><news:title>SPIN Meta-Analysis Validates Social Anxiety Screening in Trials</news:title><news:keywords>social phobia inventory, SPIN, social anxiety disorder, psychometric validation, psychedelic clinical trials, MDMA, psilocybin, cutoff calibration, regulatory endpoints, mental health assessment</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/ketamine-enhances-approach-avoidance-decision-making-in-healthy-adults-20261120-61126</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-22T22:04:49.403929+00:00</news:publication_date><news:title>Ketamine Enhances Approach-Avoidance Decision-Making in Healthy Adults</news:title><news:keywords>ketamine, approach-avoidance conflict, decision-making, lorazepam, clinical trials, mechanism of action, psychedelic research, mood disorders, neuroscience, policy implications</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/5-ht2a-receptor-deletion-alters-hippocampal-pv-and-anxiety-in-mice-20261120-61113</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-22T22:04:40.190529+00:00</news:publication_date><news:title>5-HT2A Receptor Deletion Alters Hippocampal PV and Anxiety in Mice</news:title><news:keywords>5-ht2a receptor, parvalbumin interneurons, anxiety-like behavior, psychedelic therapeutics, energy metabolism, perineuronal nets, biomarker development, clinical trial design, mouse model, serotonin signaling</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/mechanism-aligned-ketamine-therapy-2026-update-for-trd-20261120-60866</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-21T22:06:51.419375+00:00</news:publication_date><news:title>Mechanism-Aligned Ketamine Therapy: 2026 Update for TRD</news:title><news:keywords>ketamine therapy, treatment-resistant depression, mechanism-aligned care, neuroplasticity, psychedelic therapy, clinical protocols, safety considerations, patient selection, contextual integration</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/lsd-clinical-trials-global-phase-3-efforts-and-evidence-gaps-20261120-60820</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-21T22:05:59.479457+00:00</news:publication_date><news:title>LSD Clinical Trials: Global Phase 3 Efforts and Evidence Gaps</news:title><news:keywords>lsd clinical trials, phase 3 lsd studies, microdosing efficacy, anxiety and depression, pain disorders, psychedelic research, regulatory challenges, trial design, evidence gaps</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/hhs-unveils-major-federal-funding-for-psychedelic-research-ibogaine-emphasis-20261120-60821</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-21T22:05:49.798432+00:00</news:publication_date><news:title>HHS Unveils Major Federal Funding for Psychedelic Research, Ibogaine Emphasis</news:title><news:keywords>hhs psychedelic funding, ibogaine research, nimh grants, arpa-h, psychedelic clinical trials, federal policy, mental health innovation, rapid-acting psychotropics, ptsd treatment research</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/compass-pathways-faces-fda-approval-and-dea-scheduling-hurdles-in-us-20261120-60779</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-21T15:03:53.181538+00:00</news:publication_date><news:title>Compass Pathways Faces FDA Approval and DEA Scheduling Hurdles in US</news:title><news:keywords>compass pathways, fda approval, dea scheduling, psilocybin therapy, controlled substances act, treatment-resistant depression, drug policy, clinical trials, rem, psychedelic medicine</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/dutch-trd-care-diverges-from-guidelines-implications-for-psychedelic-therapies-20261119-61082</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-22T22:05:24.419095+00:00</news:publication_date><news:title>Dutch TRD Care Diverges from Guidelines: Implications for Psychedelic Therapies</news:title><news:keywords>treatment-resistant depression, clinical guidelines, real-world evidence, netherlands, pharmacological treatment, psychedelic-assisted therapy, implementation science, mental health policy</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/translational-limits-of-animal-models-in-psychedelic-research-20261119-61031</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-22T15:05:14.406572+00:00</news:publication_date><news:title>Translational Limits of Animal Models in Psychedelic Research</news:title><news:keywords>animal models, psychedelic research, translational challenges, preclinical studies, human clinical trials, regulatory policy, safety assessment, serotonin receptors, drug development, neuroscience</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/nirs-water-analysis-implications-for-psychedelic-drug-quality-control-20261119-60841</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-22T15:05:05.862707+00:00</news:publication_date><news:title>NIRS Water Analysis: Implications for Psychedelic Drug Quality Control</news:title><news:keywords>near-infrared spectroscopy, water analysis, pharmaceutical quality control, psychedelic manufacturing, regulatory compliance, analytical quality by design, critical quality attributes, nutraceutical authenticity, ICH Q14, process analytical technology</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/glymphatic-system-as-a-novel-target-in-treatment-resistant-depression-20261119-60857</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-22T15:04:55.481194+00:00</news:publication_date><news:title>Glymphatic System as a Novel Target in Treatment-Resistant Depression</news:title><news:keywords>glymphatic system, treatment-resistant depression, psychedelics, ketamine, sleep architecture, astrocytes, major depressive disorder, neuroimaging, biomarkers, clinical research</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/second-generation-nmdar-pams-implications-for-neuropsychiatric-drug-development-20261119-60867</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-22T15:04:46.887615+00:00</news:publication_date><news:title>Second-Generation NMDAR PAMs: Implications for Neuropsychiatric Drug Development</news:title><news:keywords>nmdar positive allosteric modulators, thieno[2,3-d]pyrimidin-4-one derivatives, neuropsychiatric drug development, glun2d subunit, rapid-acting antidepressants, preclinical research, oral bioavailability, cns therapeutics, mechanistic insights, translational challenges</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/simulated-weightlessness-depersonalisation-and-the-self-implications-for-psyched-20261119-60858</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-22T15:04:36.852581+00:00</news:publication_date><news:title>Simulated Weightlessness, Depersonalisation, and the Self: Implications for Psychedelic Neuroscience</news:title><news:keywords>simulated weightlessness, depersonalisation, vestibular system, ego dissolution, psychedelic research, gravity neuroscience, multisensory integration, altered states of consciousness, cambridge depersonalisation scale, space medicine</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/historeceptomics-sheds-light-on-ketamine-s-brain-targets-20261119-60860</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-22T15:04:17.197017+00:00</news:publication_date><news:title>Historeceptomics Sheds Light on Ketamine's Brain Targets</news:title><news:keywords>ketamine, historeceptomics, nmda receptor, antidepressant mechanism, brain region mapping, clinical implications, psychedelic research, drug development, adverse effects, policy</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/translational-gaps-in-animal-models-for-psychedelic-research-20261119-60822</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-21T22:07:20.560589+00:00</news:publication_date><news:title>Translational Gaps in Animal Models for Psychedelic Research</news:title><news:keywords>animal models, psychedelic research, translational gap, set and setting, preclinical studies, behavioral assays, individual differences, social context, regulatory science, experimental design</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/psychedelic-assisted-treatment-for-suds-evidence-and-gaps-2026-review-20261119-60824</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-21T22:07:11.736436+00:00</news:publication_date><news:title>Psychedelic-Assisted Treatment for SUDs: Evidence and Gaps (2026 Review)</news:title><news:keywords>psychedelic-assisted therapy, substance use disorders, clinical trials, policy, public health, psilocybin, regulatory oversight, treatment efficacy, integration with psychotherapy, risk assessment</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/shared-astrocytic-signalling-pathways-in-diverse-psychoactives-insights-from-mul-20261119-60856</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-21T22:07:02.036416+00:00</news:publication_date><news:title>Shared Astrocytic Signalling Pathways in Diverse Psychoactives: Insights from Multi-Omics Analysis</news:title><news:keywords>astrocytes, psychoactive drugs, multi-omics, psilocin, substance use disorder, cytoskeletal signalling, rho-gtpase, neurobiology, translational research</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/biosynthetic-pathway-discovery-for-carbolines-in-ayahuasca-plants-20261119-60859</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-21T22:06:30.477960+00:00</news:publication_date><news:title>Biosynthetic Pathway Discovery for β-Carbolines in Ayahuasca Plants</news:title><news:keywords>β-carboline biosynthesis, ayahuasca research, DMT production, psychedelic clinical trials, plant biotechnology, standardized psychedelics, conservation, regulatory implications, intellectual property, indigenous rights</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/distinct-brain-reconfiguration-after-psilocybin-vs-escitalopram-in-depression-ne-20261119-60823</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-21T22:06:19.178985+00:00</news:publication_date><news:title>Distinct Brain Reconfiguration After Psilocybin vs. Escitalopram in Depression: New fMRI Modelling Insights</news:title><news:keywords>psilocybin, escitalopram, major depressive disorder, fMRI, brain network reconfiguration, vortex-space modelling, biomarkers, clinical trials, psychedelic mechanisms</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/psilocybin-as-a-cgrp-inhibitor-in-hnscc-preclinical-insights-20261119-60861</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-21T22:06:10.320463+00:00</news:publication_date><news:title>Psilocybin as a CGRP Inhibitor in HNSCC: Preclinical Insights</news:title><news:keywords>psilocybin, cgrp inhibition, head and neck squamous cell carcinoma, neuroimmune oncology, tumor microenvironment, preclinical research, immunotherapy, serotonin, psychedelic compounds, translational research</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/synaptic-plasticity-and-engram-mechanisms-implications-for-psychedelic-research-20261118-61130</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-22T22:05:34.231806+00:00</news:publication_date><news:title>Synaptic Plasticity and Engram Mechanisms: Implications for Psychedelic Research</news:title><news:keywords>synaptic plasticity, engram, episodic memory, psychedelic research, memory disorders, clinical trials, neuroscience tools, memory consolidation, regulatory science</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/stagic-advances-brain-circuit-modeling-for-psychedelic-research-20261118-60830</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-22T15:05:23.740266+00:00</news:publication_date><news:title>StaGIC Advances Brain Circuit Modeling for Psychedelic Research</news:title><news:keywords>stagic, brain circuit modeling, psychedelic research, structural connectivity, functional connectivity, neuroimaging biomarkers, clinical trials, computational psychiatry, diffusion mri, circuit heterogeneity</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/compassion-outcomes-in-psychedelic-therapy-evidence-and-gaps-20261118-60843</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-22T15:04:27.036494+00:00</news:publication_date><news:title>Compassion Outcomes in Psychedelic Therapy: Evidence and Gaps</news:title><news:keywords>self-compassion, compassion for others, psychedelic therapy, mdma, psilocybin, clinical trials, mechanistic studies, measurement gaps, therapeutic outcomes, regulatory implications</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/non-hallucinogenic-psychedelic-analogs-for-depression-mechanisms-and-implication-20261118-60833</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-21T22:06:41.429630+00:00</news:publication_date><news:title>Non-Hallucinogenic Psychedelic Analogs for Depression: Mechanisms and Implications</news:title><news:keywords>non-hallucinogenic psychedelics, antidepressant analogs, neuroplasticity, 5-HT2A receptor, drug design, depression treatment, regulatory barriers, clinical trials, psychoplastogens</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/monoamine-targeting-drugs-for-ptsd-efficacy-mechanisms-and-implications-20261118-60592</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-21T15:04:17.428400+00:00</news:publication_date><news:title>Monoamine-Targeting Drugs for PTSD: Efficacy, Mechanisms, and Implications</news:title><news:keywords>ptsd, monoamine targeting drugs, ssri, sertraline, paroxetine, off-label treatments, psychedelic therapeutics, mechanistic rationale, clinical trials, treatment gaps</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/prescribed-safer-supply-in-british-columbia-early-outcomes-and-policy-implicatio-20261118-60611</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-21T15:04:04.935422+00:00</news:publication_date><news:title>Prescribed Safer Supply in British Columbia: Early Outcomes and Policy Implications</news:title><news:keywords>prescribed safer supply, british columbia, harm reduction, depression, unregulated substance use, public health policy, cohort study, drug policy, service integration</news:keywords></news:news></url><url><loc>https://mindmedicinelaw.com/briefing/ketamine-augmented-psychotherapy-and-neurocognition-in-unipolar-depression-2026--20261117-60877</loc><news:news><news:publication><news:name>The Psychedelic Journal</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-22T15:05:33.910417+00:00</news:publication_date><news:title>Ketamine-Augmented Psychotherapy and Neurocognition in Unipolar Depression: 2026 Scoping Review</news:title><news:keywords>ketamine-augmented psychotherapy, unipolar depression, neurocognitive outcomes, scoping review, treatment-resistant depression, clinical trial design, cognitive assessment, psychedelic research, evidence mapping</news:keywords></news:news></url></urlset>